Premium
Meta‐analysis of short‐term high versus low doses of atorvastatin preventing contrast‐induced acute kidney injury in patients undergoing coronary angiography/percutaneous coronary intervention
Author(s) -
Wu Hongjiang,
Li Dongmei,
Fang Minhua,
Han Hongguang,
Wang Huishan
Publication year - 2015
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/jcph.411
Subject(s) - atorvastatin , medicine , percutaneous coronary intervention , contrast induced nephropathy , acute kidney injury , conventional pci , randomized controlled trial , nephropathy , cochrane library , cardiology , incidence (geometry) , urology , myocardial infarction , endocrinology , diabetes mellitus , physics , optics
This study aimed to investigate the impact of different doses of atorvastatin on contrast‐induced acute kidney injury (CI‐AKI) in patients undergoing coronary angiography (CAG) or percutaneous coronary intervention (PCI) requiring contrast media by performing a meta‐analysis. We searched the PubMed, EMBASE, Cochrane Library, Wanfang database, China National Knowledge Infrastructure, and VIP database through April 2014. Only randomized controlled trials (RCTs) comparing short‐term high‐dose atorvastatin with low‐dose atorvastatin on CI‐AKI were selected. The main outcomes were the change of acute kidney injury markers and the incidence of contrast‐induced nephropathy (CIN). We combined 14 RCTs consisting of 1,689 patients. Compared with the low‐dose atorvastatin, high‐dose atorvastatin treatment was associated with a reduction in serum creatinine levels (weighted mean differences [WMD]‐0.1 mg/dL; 95%CI −0.14 to −0.05). In addition, high‐dose atorvastatin treatment was also associated with a lower incidence of CIN (risk ratios 0.41; 95%CI 0.29–0.56). This meta‐analysis suggests that short‐term high‐dose atorvastatin therapy appears to be superior to the low‐dose atorvastatin in preventing CI‐AKI among patients undergoing CAG/PCI requiring contrast media.